| Predictive values of m6A-fatty-acid-metabolism-related lncRNA in prognosis and immune efficiency of colon cancer |
| Received:November 05, 2023 Revised:December 12, 2023 Click here to download the full text |
| Citation of this paper:SHEN Chaoqin,LIU Taotao.Predictive values of m6A-fatty-acid-metabolism-related lncRNA in prognosis and immune efficiency of colon cancer[J].Chinese Journal of Clinical Medicine,2024,31(1):68-77 |
| Hits: 408 |
| Download times: 147 |
|
| Abstract:Objective To explore the m6A-fatty-acid-metabolism-related lncRNAs in colon cancer, and to analyze their correlation with colon cancer prognosis and tumor immune microenvironment, thus providing new molecular targets for diagnosis and treatment of colon cancer patients. Methods Transcriptome data and relevant clinical information of colon cancer patients were downloaded from TCGA database. m6A-fatty-acid-metabolism-related lncRNAs were identified through Pearson correlation analysis. The risk model based on lncRNA expression was established using univariate Cox regression analysis, LASSO regression analysis, and multivariate Cox regression analysis. The validity of the prognostic risk model was verified using Kaplan-Meier survival analysis, ROC curve, and nomogram. The immune cell infiltration was compared between high-risk and low-risk groups. Results 670 m6A-related lncRNAs and 1 011 fatty-acid-metabolism-related lncRNAs were identified from TCGA, and 39 lncRNAs of their intersection had prognostic significance. A risk model containing 5 lncRNAs related to m6A modification and fatty acid metabolism was established using LASSO and multivariate Cox regression analysis. Colon cancer patients with higher risk scores were more likely to have a worse prognosis than those with lower risk scores. Multivariate Cox regression analysis indicated that the risk score was an independent prognostic factor for colon cancer (HR=11.8, 95%CI 3.6-38.7). ROC analysis manifested that the area under curve (AUC) of the model predicting survival rate at 1, 3 and 5 years were 0.758 (95%CI 0.611-0.905), 0.793 (95%CI 0.708- 0.877) and 0.815 (95%CI 0.722-0.907). Compared with the high-risk group, the low-risk group had increased M1 macrophages (P<0.05) and higher expression of immune checkpoints (CD44, TNFRSF9, CD40LG, CD48, CD244, IDO1, HAVCR2, CD27, ICOS, LAIR1, TMIGD2, CD28 and TIGIT; P<0.05). Conclusions This m6A-fatty-acid-metabolism-related lncRNA risk model could be used to predict prognosis and immunotherapy response of colon cancer patients. |
| keywords:colon cancer m6A long non-coding RNA fatty acid metabolism immunotherapy |
| HTML View Full Text View/Add Comment Download reader |
|
|
|